Page 5,518«..1020..5,5175,5185,5195,520..5,5305,540..»

Biovista and DART Therapeutics Enter into Drug Repositioning Collaboration Targeting Duchenne Muscular Dystrophy

Posted: Published on March 27th, 2013

CHARLOTTESVILLE, Virginia and CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ -- DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), and Biovista, a leader in systematic drug repositioning, announced today that they have entered into a research collaboration to identify and develop novel drug repositioning candidates for DMD using Biovista's Clinical Outcome Search Space (COSS) technology. Under the terms of the agreement, Biovista will identify novel repositioning candidates and DART Therapeutics will have the option to select a certain number for further development. The terms of the agreement include an upfront and downstream success payments. "Drug repositioning is a major approach in our overall strategy to identify novel treatments for DMD as efficiently as possible," said Gene Williams, chief executive officer of DART Therapeutics. "Biovista and the COSS technology are leaders in systematic repositioning, ensuring for us the broadest possible coverage of repositioning opportunities that can have real impact for patients and their families awaiting treatment for DMD." "DART Therapeutics represents a unique model, being the development arm of a major patient advocacy group. Their leadership in DMD is an excellent compliment to our drug repositioning capabilities," said Aris Persidis, President of Biovista. … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Biovista and DART Therapeutics Enter into Drug Repositioning Collaboration Targeting Duchenne Muscular Dystrophy

Pioneering research into Duchenne muscular dystrophy secures commercial funding

Posted: Published on March 27th, 2013

Public release date: 27-Mar-2013 [ | E-mail | Share ] Contact: Tanya Gubbay tanya.gubbay@rhul.ac.uk Royal Holloway, University of London Royal Holloway, is today (Wednesday) giving money generated by its research into Duchenne muscular dystrophy to the Muscular Dystrophy Campaign. Families affected by the condition are also visiting laboratories on campus to find out from the scientists about new drug developments and see the work being carried out. Affecting just 1 in 3000 young boys, Duchenne muscular dystrophy is a life-shortening condition, which causes muscles to weaken and waste over time leading to increasingly severe disability. Professor George Dickson from the School of Biological Sciences at Royal Holloway has been leading a team of scientists looking into pioneering treatments, including exon skipping, a process that looks to encourage cellular machinery to 'skip over' an exon which makes up part of the gene. It is thought that by skipping one or two exons, it may be possible to treat around 83% of the genetic errors causing Duchenne muscular dystrophy. A pharmaceutical company is now looking to collaborate with the team to develop drugs that could be used for treating the condition and has paid a fee to secure rights to the research. … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Pioneering research into Duchenne muscular dystrophy secures commercial funding

Natural Seizure Remedies – Video

Posted: Published on March 27th, 2013

Natural Seizure Remedies These are some of the natural seizure remedies that didn't work for me as well as the one that is currently work for me. Check out my journey at http://melin... By: Melinda Curle … Continue reading

Comments Off on Natural Seizure Remedies – Video

100% NATURAL – Video

Posted: Published on March 27th, 2013

100% NATURAL 370000 usd. By: luis alarcon … Continue reading

Comments Off on 100% NATURAL – Video

New resource promises information, education and inspiration when it comes to epilepsy in Canada

Posted: Published on March 27th, 2013

E-Action designed for the 300,000 living with the neurological disorder1 OAKVILLE, ON, March 26, 2013 /CNW/ - Canadians with epilepsy, as well as their family, friends and caregivers, now have an exciting new information source and support network. E-Action - Taking Action Against Epilepsy strives to provide a caring and informative environment for those touched by the disorder. E-Action includes a broad range of interactive education and information resources, including a magazine, a website, a mobile application (App), and a leader program that features 10 inspirational Canadians living well with epilepsy. "Epilepsy associations across the country have been working tirelessly to help people with epilepsy live the best quality of life possible. E-Action is a fantastic resource to help us do just that," said Gail Dempsey, President, Canadian Epilepsy Alliance (CEA). "The program will go a long way in raising the profile of epilepsy, and ensuring that those living with the disorder can connect with the medical community, local epilepsy agencies, and their wider communities to obtain the best care and treatment available." E-Action is an initiative of UCB Canada Inc., a global biopharmaceutical company committed to improving the lives of people with epilepsy, one of the most common neurological … Continue reading

Comments Off on New resource promises information, education and inspiration when it comes to epilepsy in Canada

New Autism Registry Hopes to Boost Research Participation Rates

Posted: Published on March 27th, 2013

Newswise COLUMBUS, Ohio. Each year, only five percent of the estimated 1.5 million children with an autism spectrum disorder in the US participate in clinical research studies. This is in stark contrast to pediatric cancer studies, which have a nearly 90 percent enrollment rate a rate that has helped advance treatment and outcomes for childhood cancers substantially in the last decade. In an effort to accelerate similar progress within the autism community, a group of academic medical centers has collaborated to launch an Autism Spectrum Disorder (ASD) sub-registry within ResearchMatch, a disease-neutral national database connecting patients with ongoing research. The new ASD sub-registry helps act as a matchmaker, linking families with autism researchers around the nation. Registration on ResearchMatch takes about 5 minutes and is open to volunteers of all ages and conditions including volunteers without health conditions. If we could raise the autism research participation level to that of the pediatric cancer community, we think we could realize similar gains in new knowledge, treatments and outcomes, said Rose Hallarn, Program Director for Clinical Trials Recruitment at the Center for Clinical and Translational Science (CCTS) at The Ohio State University and Institutional Liaison for ResearchMatch. Working with researchers at Vanderbilt … Continue reading

Comments Off on New Autism Registry Hopes to Boost Research Participation Rates

Parents hope new state autism plan helps children toward their goals

Posted: Published on March 27th, 2013

A new state plan that brings autism to the forefront has given the disability much-needed recognition, and it will be up to the culture of Michigan to determine how the plan will affect real people, an author of the plan said. The Michigan Department of Community Health and the Michigan Autism Council released the Michigan Autism Spectrum Disorders Plan last week in advance of Autism Awareness Month in April. The plan was warranted because of recent legislation providing insurance coverage for autism treatment, and because the condition is on the rise, said Dr. Mary Sharp, advocacy and community development officer for the Autism Alliance of Michigan and an author of the plan. The incidence of the behavioral disorder now is one in 88 children, according to the Centers for Disease Control and Prevention, or 50,000 people in Michigan including 16,000 in schools, according to a state news release. Midlander Trisha Fenbys 13-year-old daughter, Hollie Kayden, is one of those 16,000 students. Fenbys goals for her daughter arent much different from those of other parents: to give Hollie the tools to have a meaningful life and a decent job. But Hollie is struggling, her mother said. She began in regular education, … Continue reading

Comments Off on Parents hope new state autism plan helps children toward their goals

Letters: Autism research

Posted: Published on March 27th, 2013

In the past year, groundbreaking research has uncovered precise genetic links between autism and Fragile X syndrome, giving families like ours hope that treatment for many of the core symptoms of both conditions is on the horizon. New drugs currently in clinical trials have been shown to have a significant effect on reducing the symptoms of severe social impairment in people with autism or Fragile X syndrome. Reducing repetitive behaviors and improving social skills would allow our family members to lead more independent lives. While most people know about autism and autism spectrum disorders, not as many are aware of Fragile X syndrome. Fragile X is closely related to autism, is the most common inherited cause of intellectual disabilities and is the most common genetic cause of autism. It is imperative that the advancements made through these groundbreaking research projects continue to be built upon. Wise stewardship of federal research dollars would encourage continued investment and expand the scope of research into the links between Fragile X and autism. The promise of this research gives hope to many of us in Utah who have family members with autism and Fragile X syndrome that independence and social acceptance are within reach … Continue reading

Comments Off on Letters: Autism research

Acute Stroke Therapy Used Three Times More at Certified Primary Stroke Centers

Posted: Published on March 27th, 2013

Newswise PHILADELPHIA - Certified Primary Stroke Centers are three times more likely to administer clot-busting treatment for strokes than non-certified centers, reports a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania. The study, published in the Journal of the American Heart Association, looked at a wide sample of hospitals across the United States, and provides insight into practice across the US health care system as experts examine ways to increase the use of this important therapy. Clot busting treatment is used to open blocked blood vessels, restoring blood flow to the brain and reducing disability after stroke. Less than half of ischemic stroke patients who are eligible for the treatment, recombinant tissue plasminogen activator (rt-PA), actually receive it. Currently, only a small percentage of stroke patients receive rt-PA therapy. "We found that primary stroke centers administered rt-PA at a much higher rate than other hospitals, demonstrating one way that certified centers are succeeding." said Michael T. Mullen, MD, the studys lead author and an assistant professor of Neurology at the Perelman School of Medicine at the University of Pennsylvania. Primary Stroke Centers, certified through The Joint Commission, used rt-PA in 6.7 percent of … Continue reading

Comments Off on Acute Stroke Therapy Used Three Times More at Certified Primary Stroke Centers

Certified stroke centers more likely to give clot-busting drugs

Posted: Published on March 27th, 2013

Mar. 26, 2013 Stroke patients are three times more likely to receive clot-busting medication if treated at a certified stroke center, according to a study in the Journal of the American Heart Association. Intravenous tissue plasminogen activator (tPA) is the only drug approved by the Food and Drug Administration for emergency treatment for people who have ischemic (clot-caused) stroke. The durg can reduce stroke disability. "The stroke center concept has rapidly taken off, and this data demonstrates one way that certified centers are doing better than non-certified centers," said Michael T. Mullen, M.D., the study's lead author and an assistant professor of neurology at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. The researchers examined hospital discharge data on 323,228 ischemic stroke patients from 26 states in 2004-09. The clot-buster was administered to: After researchers adjusted for patient and facility characteristics, they found the likelihood of receiving tPA was still almost twice as high in certified stroke centers. Over time, tPA use increased from 6 percent to 7.6 percent at certified primary stroke centers and 1.4 percent to 3.3 percent at non-certified hospitals. During a stroke, blood flow must be restored quickly and tPA can only … Continue reading

Comments Off on Certified stroke centers more likely to give clot-busting drugs

Page 5,518«..1020..5,5175,5185,5195,520..5,5305,540..»